Cargando…
In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron
Omicron was designated by the WHO as a VOC on 26 November 2021, only 4 days after its sequence was first submitted. However, the impact of Omicron on current antibodies and vaccines remains unknown and evaluations are still a few weeks away. We analysed the mutations in the Omicron variant against e...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876352/ https://www.ncbi.nlm.nih.gov/pubmed/35215983 http://dx.doi.org/10.3390/v14020390 |
_version_ | 1784658150272532480 |
---|---|
author | Hu, Ye-Fan Hu, Jing-Chu Chu, Hin Yau, Thomas Zhang, Bao-Zhong Huang, Jian-Dong |
author_facet | Hu, Ye-Fan Hu, Jing-Chu Chu, Hin Yau, Thomas Zhang, Bao-Zhong Huang, Jian-Dong |
author_sort | Hu, Ye-Fan |
collection | PubMed |
description | Omicron was designated by the WHO as a VOC on 26 November 2021, only 4 days after its sequence was first submitted. However, the impact of Omicron on current antibodies and vaccines remains unknown and evaluations are still a few weeks away. We analysed the mutations in the Omicron variant against epitopes. In our database, 132 epitopes of the 120 antibodies are classified into five groups, namely NTD, RBD-1, RBD-2, RBD-3, and RBD-4. The Omicron mutations impact all epitopes in NTD, RBD-1, RBD-2, and RBD-3, with no antibody epitopes spared by these mutations. Only four out of 120 antibodies may confer full resistance to mutations in the Omicron spike, since all antibodies in these three groups contain one or more epitopes that are affected by these mutations. Of all antibodies under EUA, the neutralisation potential of Etesevimab, Bamlanivimab, Casirivimab, Imdevima, Cilgavimab, Tixagevimab, Sotrovimab, and Regdanvimab might be dampened to varying degrees. Our analysis suggests the impact of Omicron on current therapeutic antibodies by the Omicron spike mutations may also apply to current COVID-19 vaccines. |
format | Online Article Text |
id | pubmed-8876352 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88763522022-02-26 In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron Hu, Ye-Fan Hu, Jing-Chu Chu, Hin Yau, Thomas Zhang, Bao-Zhong Huang, Jian-Dong Viruses Brief Report Omicron was designated by the WHO as a VOC on 26 November 2021, only 4 days after its sequence was first submitted. However, the impact of Omicron on current antibodies and vaccines remains unknown and evaluations are still a few weeks away. We analysed the mutations in the Omicron variant against epitopes. In our database, 132 epitopes of the 120 antibodies are classified into five groups, namely NTD, RBD-1, RBD-2, RBD-3, and RBD-4. The Omicron mutations impact all epitopes in NTD, RBD-1, RBD-2, and RBD-3, with no antibody epitopes spared by these mutations. Only four out of 120 antibodies may confer full resistance to mutations in the Omicron spike, since all antibodies in these three groups contain one or more epitopes that are affected by these mutations. Of all antibodies under EUA, the neutralisation potential of Etesevimab, Bamlanivimab, Casirivimab, Imdevima, Cilgavimab, Tixagevimab, Sotrovimab, and Regdanvimab might be dampened to varying degrees. Our analysis suggests the impact of Omicron on current therapeutic antibodies by the Omicron spike mutations may also apply to current COVID-19 vaccines. MDPI 2022-02-14 /pmc/articles/PMC8876352/ /pubmed/35215983 http://dx.doi.org/10.3390/v14020390 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Hu, Ye-Fan Hu, Jing-Chu Chu, Hin Yau, Thomas Zhang, Bao-Zhong Huang, Jian-Dong In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron |
title | In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron |
title_full | In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron |
title_fullStr | In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron |
title_full_unstemmed | In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron |
title_short | In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron |
title_sort | in-silico analysis of monoclonal antibodies against sars-cov-2 omicron |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876352/ https://www.ncbi.nlm.nih.gov/pubmed/35215983 http://dx.doi.org/10.3390/v14020390 |
work_keys_str_mv | AT huyefan insilicoanalysisofmonoclonalantibodiesagainstsarscov2omicron AT hujingchu insilicoanalysisofmonoclonalantibodiesagainstsarscov2omicron AT chuhin insilicoanalysisofmonoclonalantibodiesagainstsarscov2omicron AT yauthomas insilicoanalysisofmonoclonalantibodiesagainstsarscov2omicron AT zhangbaozhong insilicoanalysisofmonoclonalantibodiesagainstsarscov2omicron AT huangjiandong insilicoanalysisofmonoclonalantibodiesagainstsarscov2omicron |